Status:
COMPLETED
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
Lead Sponsor:
Nxera Pharma UK Limited
Collaborating Sponsors:
Allergan
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55-85 years
Phase:
PHASE1
Brief Summary
Multi-centre study of HTL0018318 in patients with Alzheimer's disease as an add-on to standard-of-care
Detailed Description
This is a multi-centre study conducted in four countries. A total of 60 subjects with Alzheimer's disease who are on standard-of-care will be enrolled to receive one of 3 active HTL0018318 or placebo ...
Eligibility Criteria
Inclusion
- Diagnostic evidence of Alzheimer's disease according to the 2011 National Institutes of Aging-Alzheimer's Association (NIA-AA) criteria
- Participants with Alzheimer's disease on stable standard of care
Exclusion
- Presence of illness apart from Alzheimer's disease that could contribute to cognitive dysfunction
- A current or history of clinically significant suicidal ideation within the past 6 months
- Subjects who have been on anti-cholinergic and/or anti muscarinic treatment
Key Trial Info
Start Date :
November 10 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 16 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03456349
Start Date
November 10 2017
End Date
July 16 2018
Last Update
July 20 2018
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Syneos
Prague, Czechia
2
Syneos
Warsaw, Poland
3
Syneos
Bratislava, Slovakia
4
Syneos
Barcelona, Spain